

# STRUCTURAL ELUCIDATION OF MANNAN (POLYMANNOSE) CONJUGATE WITH THE MYELIN OLIGODENDROCYTE GLYCOPROTEIN 35-55 EPI TOPE (MOG<sub>35-55</sub>) USING NMR SPECTROSCOPY

Nikoletta Zoupanou<sup>\*</sup>, Areti Gkika<sup>\*\*</sup>, Maria-Eleni Androutsou<sup>\*\*\*</sup>, Theodore Tselios<sup>\*\*</sup>,  
Thomas Mavromoustakos<sup>\*</sup>

<sup>\*</sup> *Department of Chemistry, National and Kapodistrian University of Athens, 10679 Athens, Greece*

<sup>\*\*</sup> *Department of Chemistry, University of Patras, 26504 Rion Patras, Greece*

<sup>\*\*\*</sup> *Vianex S.A., Tatoiou Str., 18th km Athens-Lamia National Road, Nea Erythrea, 14671, Greece*

**e-mail:** [nikolzoup@chem.uoa.gr](mailto:nikolzoup@chem.uoa.gr)

Multiple sclerosis (MS) is an immunologically mediated [1], inflammatory, autoimmune disorder of the Central Nervous System (CNS) and it is characterized by destruction of the myelin sheath leading to paralysis and serious health problems. One of the main proteins of myelin is the myelin oligodendrocyte glycoprotein MOG and is heavily implicated in the progress of MS. MOG protein is associated with the demyelination in animals in Experimental Autoimmune Encephalomyelitis (EAE). The 35-55 epitope of MOG protein is considered to be a main autoantigen in the pathogenesis of MS and is connected with the induction of EAE in mice. This epitope conjugated with polysaccharide mannan in its oxidized form, was found to protect mice from EAE and could be a promising approach for the immunotherapy of MS [2]. Mannose, mannan polysaccharide, oxidized mannan and the conjugates of immunodominant MOG<sub>35-55</sub> epitope with-mannan in oxidized form were studied by high field Nuclear Magnetic Resonance (NMR) spectroscopy to explore their structural characteristics. This study was also used to detect any structural alteration in the conjugates during storage conditions.

**Keywords:** multiple sclerosis; myelin oligodendrocyte glycoprotein; nuclear magnetic resonance

## References

[1] Androutsou, M.E. et al. *Med. Chem.*, **2018**, 14, 120-128

[2] Tseveleki, V. et al. L. *Exp Neurol.*, **2015**, 267, 254-267